River Associates (NASDAQ: CRAI), a worldwide leader in providing economic,
financial, and management consulting services , today announced
financial results for the fiscal fourth quarter and year ended January
Trial is recruiting biomarker-selected patients previously treated with two lines of therapy for locally advanced or metastatic disease Merrimack's first study to prospectively select patients based on heregulin status
CAMBRIDGE, Mass., Feb.
Voyager Legend UC is optimized to work with Microsoft Lync, together providing a simple-to-use, superior user experience.
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine
platform company developing targeted and programmable therapeutics
called Accurins TM , announced today that Andrew Hirsch, BIND’s
chief operating officer and chief financial officer, will present at the
Cowen & Co.
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye, today announced that Amar
Sawhney, Ph.D., President and Chief Executive Officer, will participate
in two upcoming conferences:
A live audio webcast of the presentations can be accessed through the
Calendar of Events section of the Company's website at investors.ocutx.com .
Visa Inc. today announced that Visa
Checkout will become available in a total of 16 markets in 2015,
continuing the early momentum the product has seen since launching in
three markets in the summer of 2014.
DirecTV's stock (DTV) gained 1% in premarket trade Thursday, after the satellite TV service beat fourth-quarter profit expectations amid strong growth in average monthly revenue per subscriber (ARPU). For the quarter ended Dec.
Ultra Petroleum Increases Proved Reserves 49 Percent To 5.4 Tcfe And Reports 72 Percent Increase In PV-10 Value To $7.1 Billion Canada NewsWire
2014 All-In F&D Costs of $0.75 per Mcfe and 805 Percent Reserve Replacement Ratio HOUSTON , Feb.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.